JP2022523045A - ツカチニブを用いて乳がんを処置する方法 - Google Patents

ツカチニブを用いて乳がんを処置する方法 Download PDF

Info

Publication number
JP2022523045A
JP2022523045A JP2021543165A JP2021543165A JP2022523045A JP 2022523045 A JP2022523045 A JP 2022523045A JP 2021543165 A JP2021543165 A JP 2021543165A JP 2021543165 A JP2021543165 A JP 2021543165A JP 2022523045 A JP2022523045 A JP 2022523045A
Authority
JP
Japan
Prior art keywords
subject
months
protein
cytochrome
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523045A5 (https=
JPWO2020159822A5 (https=
Inventor
ウォーカー，ルーク
エンドレス，クリストファー，ジェイ．
ジェヨン リ，アンソニー，
スン，ハオ
トプレツ－エリクソン，アリエル，アール．
Original Assignee
シージェン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シージェン インコーポレイテッド filed Critical シージェン インコーポレイテッド
Publication of JP2022523045A publication Critical patent/JP2022523045A/ja
Publication of JP2022523045A5 publication Critical patent/JP2022523045A5/ja
Publication of JPWO2020159822A5 publication Critical patent/JPWO2020159822A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021543165A 2019-01-28 2020-01-24 ツカチニブを用いて乳がんを処置する方法 Pending JP2022523045A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962797854P 2019-01-28 2019-01-28
US62/797,854 2019-01-28
PCT/US2020/014953 WO2020159822A1 (en) 2019-01-28 2020-01-24 Methods of treating breast cancer with tucatinib

Publications (3)

Publication Number Publication Date
JP2022523045A true JP2022523045A (ja) 2022-04-21
JP2022523045A5 JP2022523045A5 (https=) 2023-02-02
JPWO2020159822A5 JPWO2020159822A5 (https=) 2023-02-02

Family

ID=69740562

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543165A Pending JP2022523045A (ja) 2019-01-28 2020-01-24 ツカチニブを用いて乳がんを処置する方法

Country Status (13)

Country Link
US (1) US20220193076A1 (https=)
EP (1) EP3917533A1 (https=)
JP (1) JP2022523045A (https=)
KR (1) KR20210119498A (https=)
CN (1) CN113613656A (https=)
AR (1) AR119681A1 (https=)
AU (1) AU2020215551A1 (https=)
CA (1) CA3126279A1 (https=)
IL (1) IL284850A (https=)
MX (1) MX2021008834A (https=)
SG (1) SG11202107488PA (https=)
TW (1) TW202042820A (https=)
WO (1) WO2020159822A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060407A1 (en) 2017-04-28 2018-11-01 Seattle Genetics, Inc. Treatment of her2 positive cancers
US20220125877A1 (en) * 2019-07-10 2022-04-28 Sun Yat-Sen University Method for treating colorectal cancer
US20230372342A1 (en) * 2020-09-28 2023-11-23 Seagen Inc. Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CN117243959B (zh) * 2022-10-13 2026-03-06 山东大学 治疗骨质疏松的方法和药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201016A1 (en) * 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Treatment of her2 positive cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201016A1 (en) * 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Treatment of her2 positive cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"A Study of Tucatinib (ONT-380) Combined With Capecitabine and/ or Trastuzumab in Patients With HER2+", CLINICALTRIALS, JPN6023053221, 20 December 2018 (2018-12-20), ISSN: 0005385819 *
"A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in PatientsWith Adva", CLINICALTRIALS, JPN6023053220, 10 December 2018 (2018-12-10), ISSN: 0005385818 *
RASHMI MURTHY; ET AL: "TUCATINIB WITH CAPECITABINE AND TRASTUZUMAB IN ADVANCED HER2-POSITIVE METASTATIC BREAST CANCER WITH", THE LANCET ONCOLOGY, vol. VOL:19, NR:7, JPN5022005288, 24 May 2018 (2018-05-24), NL, pages 880 - 888, ISSN: 0005232509 *

Also Published As

Publication number Publication date
IL284850A (en) 2021-08-31
AR119681A1 (es) 2022-01-05
CN113613656A (zh) 2021-11-05
KR20210119498A (ko) 2021-10-05
TW202042820A (zh) 2020-12-01
CA3126279A1 (en) 2020-08-06
EP3917533A1 (en) 2021-12-08
SG11202107488PA (en) 2021-08-30
MX2021008834A (es) 2021-09-28
AU2020215551A1 (en) 2021-08-05
WO2020159822A1 (en) 2020-08-06
US20220193076A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
JP2022523045A (ja) ツカチニブを用いて乳がんを処置する方法
US12048698B2 (en) Treatment of HER2 positive cancers
Kong et al. Phase 2 study of bortezomib combined with temozolomide and regional radiation therapy for upfront treatment of patients with newly diagnosed glioblastoma multiforme: safety and efficacy assessment
US20230310455A1 (en) Combination therapies for treatment of her2 cancer
TW202011966A (zh) 用pi3k抑制劑gdc-0077治療癌症之方法
CN114945369A (zh) 图卡替尼与抗her2抗体-药物缀合物联合治疗her2阳性乳腺癌的方法
TW202027736A (zh) 用PI3Kα抑制劑及二甲雙胍治療癌症之方法
JP6860949B2 (ja) 癌の処置方法
CN113453671A (zh) 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
KR20220125323A (ko) Ahr 억제제 및 이의 용도
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
JP2020023497A (ja) 組合せ医薬
CN111728974B (zh) 西奥罗尼用于小细胞肺癌的治疗
CN116583540A (zh) 用于治疗her2癌症的组合疗法
WO2021180055A1 (zh) 一种brd4抑制剂的用途
WO2023230429A1 (en) Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody
HK40092971A (zh) 用於治疗her2癌症的组合疗法
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
HK40045708A (en) Methods of treating cancer with pi3k alpha inhibitors and metformin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240806